Gilead Sciences Spain
在场
Gilead Sciences Spain 的所有者是 Gilead Sciences.
是其中之一......
- Forbes Global 2000 (#575);
- Fortune 500 (#154);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Gilead Sciences 是一家在股票代码 GILD (US) 下上市的公司。
Gilead Sciences 在 7 个国家有直接业务。Gilead Sciences 拥有 7家子公司，其中包括 Gilead Sciences Canada、Gilead Sciences EMEA 和 Gilead Sciences Germany。
他们在：
涉及Gilead Sciences的并购和融资。
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (公布2024二月15号).
高管
查看带有其 3 名主要高管的组织结构图
Gilead Sciences Spain 搜索最多的简介
- Maria Río Presa, General Manager
- Monica Urrutia, Human Resources Director
- Victoria Ayala Vargas, Government Affairs Director
高管在Gilead Sciences变化
- Merdad Parsey, Chief Medical Officer, 将于 20251月 退休 (新闻发布的2024七月18号).
创建提醒
跟踪 Gilead Sciences Spain 的高管变动
生物技术
Gilead Sciences 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Gilead Sciences Spain 的最新新闻稿
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- Gilead Presents Additional Efficacy Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
- Gilead to Present Late Breaking Data Highlighting Antiviral Portfolio Innovative Research Pipeline and HIV Leadership at IDWeek 2024
- Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday November 6 2024
- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
- Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
- Gilead Sciences to Present at Upcoming Investor Conferences
- Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
- Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
- View more press releases Close
通过电子邮件
